Starpharma Holdings Sustainability Profile
Starpharma Holdings Limited, headquartered in Australia, is a pioneering biotechnology company renowned for its innovative work in drug delivery and development. Founded in 1996, Starpharma has made significant strides in the pharmaceutical industry, particularly in the areas of dendrimer-based therapies and antiviral products. The company’s flagship product, VivaGel®, is a unique antiviral and antibacterial gel that has garnered attention for its efficacy in preventing sexually transmitted infections. Starpharma's commitment to research and development has positioned it as a leader in the biotech sector, with a strong focus on enhancing the safety and effectiveness of existing therapies. With a robust pipeline and strategic partnerships, Starpharma continues to expand its market presence, contributing to advancements in healthcare and improving patient outcomes globally.
DitchCarbon Score
How does Starpharma Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Starpharma Holdings's score of 16 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Starpharma Holdings's reported carbon emissions
In 2025, Starpharma Holdings, headquartered in Australia, reported total carbon emissions of approximately 323,000 kg CO2e, encompassing both Scope 1 and Scope 2 emissions. This marks a decrease from 2024, where emissions were about 357,000 kg CO2e, and from 2023, which recorded approximately 385,000 kg CO2e. For the year 2022, the company disclosed emissions of about 441,350 kg CO2e, with 25,670 kg CO2e attributed to Scope 1 and 416,680 kg CO2e to Scope 2. In 2021, emissions were approximately 481,800 kg CO2e, with 24,400 kg CO2e from Scope 1 and 457,400 kg CO2e from Scope 2. Starpharma has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The absence of such commitments suggests a need for further development in their climate strategy. Overall, the company is actively monitoring its emissions and has shown a trend of reduction over the past few years, indicating a commitment to improving its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 24,400 | 00,000 | - | - | - |
| Scope 2 | 457,400 | 000,000 | - | - | - |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Starpharma Holdings's Industry?
How Carbon Intensive is Starpharma Holdings's Location?
Starpharma Holdings's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Starpharma Holdings has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
